Nuclear factor kappa B-mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice

Blockade of CD47-mediated cathepsin S/protease-activated receptor 2 signaling provides a therapeutic target for hepatocellular carcinoma

(2014) Terence Kin-Wah Lee et al.   HEPATOLOGY

Inhibition of Akt Reverses the Acquired Resistance to Sorafenib by Switching Protective Autophagy to Autophagic Cell Death in Hepatocellular Carcinoma

(2014) B. Zhai et al.   MOLECULAR CANCER THERAPEUTICS

Cancer statistics, 2013

(2013) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Epigenetic Roles of MLL Oncoproteins Are Dependent on NF-κB

(2013) Hsu-Ping Kuo et al.   CANCER CELL

Label-retaining liver cancer cells are relatively resistant to sorafenib

(2013) Hong-Wu Xin et al.   GUT

The Enhanced Metastatic Potential of Hepatocellular Carcinoma (HCC) Cells with Sorafenib Resistance

(2013) Ariel Ka-Man Chow et al.   PLoS One

Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response

(2013) D. Tseng et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Efficacy of Using Cancer Stem Cell Markers in Isolating and Characterizing Liver Cancer Stem Cells

(2013) George S. Wilson et al.   STEM CELLS AND DEVELOPMENT

NF-κB non-cell-autonomously regulates cancer stem cell populations in the basal-like breast cancer subtype

(2013) Mizuki Yamamoto et al.   Nature Communications

Second-Line Therapies in Hepatocellular Carcinoma: Emergence of Resistance to Sorafenib

(2012) A. Villanueva et al.   CLINICAL CANCER RESEARCH

Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma

(2012) Juanjuan Shan et al.   HEPATOLOGY

The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors

(2012) S. B. Willingham et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CD24+ Liver Tumor-Initiating Cells Drive Self-Renewal and Tumor Initiation through STAT3-Mediated NANOG Regulation

(2011) Terence Kin Wah Lee et al.   Cell Stem Cell

Epithelial mesenchymal transition and hedgehog signaling activation are associated with chemoresistance and invasion of hepatoma subpopulations

(2011) Xiaoli Chen et al.   JOURNAL OF HEPATOLOGY

The Significance of Early Alpha-Fetoprotein Level Changes in Predicting Clinical and Survival Benefits in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib

(2011) T. Yau et al.   ONCOLOGIST

Synergistic Activity of Sorafenib and Sulforaphane Abolishes Pancreatic Cancer Stem Cell Characteristics

(2010) Vanessa Rausch et al.   CANCER RESEARCH

CD13 is a therapeutic target in human liver cancer stem cells

(2010) Naotsugu Haraguchi et al.   JOURNAL OF CLINICAL INVESTIGATION

CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells

(2009) Ravindra Majeti et al.   CELL

Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells

(2009) K. S. Chan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Radioprotection in Normal Tissue and Delayed Tumor Growth by Blockade of CD47 Signaling

(2009) J. B. Maxhimer et al.   Science Translational Medicine

Significance of CD90+ Cancer Stem Cells in Human Liver Cancer

(2008) Zhen Fan Yang et al.   CANCER CELL

EpCAM and  -Fetoprotein Expression Defines Novel Prognostic Subtypes of Hepatocellular Carcinoma

(2008) T. Yamashita et al.   CANCER RESEARCH

Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   JNCI-Journal of the National Cancer Institute

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE